Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interleukin 15

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Interleukin 15. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-000799-15 Sponsor Protocol Number: 04-04074 Start Date*: 2004-09-09
    Sponsor Name:Aker University Hospital
    Full Title: DOES BENFOTIAMINE SUPPLEMENTATION REDUCE SERUM LEVELS OF ADVANCED GLYCATION END PRODUCTS AND BIOCHEMICAL MARKERS OF VASCULAR DYSFUNCTION IN TYPE 1 DIABETES?
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-004554-34 Sponsor Protocol Number: 2014-004554-34 Start Date*: 2015-10-15
    Sponsor Name:Bispebjerg Hospital
    Full Title: An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam,...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003858-33 Sponsor Protocol Number: AM0010-301 Start Date*: 2017-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi...
    Medical condition: Advanced Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001074-26 Sponsor Protocol Number: S-CPR2011 Start Date*: 2011-11-17
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin
    Full Title: Effect of High Dose Selenium on Inflammation and Neurological Outcome after Cardiac Arrest: A randomized, double blind placebo controlled phase 2a study
    Medical condition: Cardiac Arrest with successful resuscitation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10007515 Cardiac arrest PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020065-24 Sponsor Protocol Number: WA25204 Start Date*: 2011-08-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) BE (Completed) AT (Completed) LT (Completed) CZ (Completed) DE (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001490-95 Sponsor Protocol Number: ESPRIT 002: STALWART Start Date*: 2006-04-21
    Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID)
    Full Title: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002744-74 Sponsor Protocol Number: F3-IROzono-COVID-19 Start Date*: 2022-06-23
    Sponsor Name:Sociedad Española de Ozonoterapia - SEOT [...]
    1. Sociedad Española de Ozonoterapia - SEOT
    2. Cátedra de Ozonoterapia y Dolor Crónico de la Universidad Católica San Antonio de Murcia - UCAM
    Full Title: Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial.
    Medical condition: COVID-19 infection requiring hospitalization
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001861-25 Sponsor Protocol Number: DIAGNODE-2(D/P2/17/6) Start Date*: 2017-06-22
    Sponsor Name:Diamyd Medical AB
    Full Title: A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005416-26 Sponsor Protocol Number: ANSWER Start Date*: 2014-06-06
    Sponsor Name:Mario Negri Institute
    Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein...
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004511-21 Sponsor Protocol Number: RC-2007-01 Start Date*: 2007-08-01
    Sponsor Name:Queen Mary University London
    Full Title: Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR]
    Medical condition: The current standard treatment in patients with metastatic renal cancer includes nephrectomy followed by immune therapy with either interleukin 2 (rIL-2) or interferon (IFN-α). Unfortunately, resp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050018 Renal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003567-31 Sponsor Protocol Number: KPUK0106 Start Date*: 2007-05-25
    Sponsor Name:Med. Klinik II, Grosshadern, Klinikum der Universität München
    Full Title: Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients
    Medical condition: hypertension metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10052066 Metabolic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002625-20 Sponsor Protocol Number: SC052021 Start Date*: 2021-08-31
    Sponsor Name:University Hospitals Leuven
    Full Title: Intrathecal morphine administration for minimally invasive pancreatic surgery: A double blind, prospective randomized placebo-controlled trial.
    Medical condition: postoperative pain treatment after minimally invasive pancreatic surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002031-29 Sponsor Protocol Number: R7257-RAA-1947 Start Date*: 2020-11-05
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ...
    Medical condition: SEVERE APLASTIC ANEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001656-41 Sponsor Protocol Number: TCeD21 Start Date*: 2022-12-07
    Sponsor Name:Topas Therapeutics GmbH
    Full Title: A double-blind, randomized, placebo-controlled, phase 2a study to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagno...
    Medical condition: Coeliac disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) FI (Completed) DE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015936-14 Sponsor Protocol Number: CH14.181021 Start Date*: 2010-03-10
    Sponsor Name:University Children´s Hospital Tübingen,
    Full Title: PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA
    Medical condition: Pediatric patients with relapsed neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021018-49 Sponsor Protocol Number: FOILED Start Date*: 2012-05-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: Fish OIL optimal dosE Determination Study
    Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040070 Septic shock PT
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003444-30 Sponsor Protocol Number: C0743T12 Start Date*: 2007-05-15
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005332-27 Sponsor Protocol Number: WA43811 Start Date*: 2022-01-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Prematurely Ended) GR (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 10:14:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA